{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:19:59Z","timestamp":1771949999969,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI113971"],"award-info":[{"award-number":["AI113971"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI139258"],"award-info":[{"award-number":["AI139258"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI147632"],"award-info":[{"award-number":["AI147632"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32AI007647"],"award-info":[{"award-number":["T32AI007647"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSN272201100016I"],"award-info":[{"award-number":["HHSN272201100016I"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG059319"],"award-info":[{"award-number":["AG059319"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.antiviral.2022.105474","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T09:27:01Z","timestamp":1669454821000},"page":"105474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Investigating N-arylpyrimidinamine (NAPA) compounds as early-stage inhibitors against human cytomegalovirus"],"prefix":"10.1016","volume":"209","author":[{"given":"Andrea J.","family":"Parsons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina I.","family":"Ophir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jailene Casado","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn R.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Kwasny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven C.","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Torhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark N.","family":"Prichard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott H.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina E.","family":"Atanasoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narendran","family":"G-Dayanandan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry L.","family":"Bowlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Opperman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-3535","authenticated-orcid":false,"given":"Domenico","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2022.105474_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211034656","article-title":"Cytomegalovirus seroprevalence among blood donors: a systematic review and meta-analysis","volume":"49","author":"Adane","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.antiviral.2022.105474_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010370","article-title":"Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers","volume":"5","author":"Arav-Boger","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2022.105474_bib3","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2022.105474_bib4","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/ac9912247","article-title":"A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates","volume":"72","author":"Bevan","year":"2000","journal-title":"Anal. Chem."},{"key":"10.1016\/j.antiviral.2022.105474_bib5","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1016\/S0960-894X(03)00586-9","article-title":"Thiourea inhibitors of herpes viruses. Part 1: bis-(aryl)thiourea inhibitors of CMV","volume":"13","author":"Bloom","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2022.105474_bib6","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1016\/j.bmcl.2004.04.093","article-title":"Thiourea inhibitors of herpes viruses. Part 2: N-Benzyl-N'-arylthiourea inhibitors of CMV","volume":"14","author":"Bloom","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.antiviral.2022.105474_bib7","first-page":"2598","article-title":"Entry of human cytomegalovirus into retinal pigment epithelial and endothelial cells by endocytosis","volume":"40","author":"Bodaghi","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.antiviral.2022.105474_bib8","series-title":"Small Molecules-Prospective Novel HCMV Inhibitors","author":"Bogner","year":"2021"},{"key":"10.1016\/j.antiviral.2022.105474_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1128\/AAC.01311-05","article-title":"Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound","volume":"51","author":"Butler","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105474_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/acs.jcim.6b00465","article-title":"Phantom PAINS: problems with the utility of alerts for pan-assay INterference CompoundS","volume":"57","author":"Capuzzi","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.antiviral.2022.105474_bib11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1128\/jvi.63.3.1435-1440.1989","article-title":"Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element","volume":"63","author":"Cherrington","year":"1989","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105474_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/rmv.574","article-title":"Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir","volume":"18","author":"Chou","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2022.105474_bib13","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105474_bib14","doi-asserted-by":"crossref","first-page":"10715","DOI":"10.1128\/JVI.01050-16","article-title":"Convallatoxin-induced reduction of methionine import effectively inhibits human cytomegalovirus infection and replication","volume":"90","author":"Cohen","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105474_bib15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/adt.2015.674","article-title":"How to triage PAINS-full research","volume":"14","author":"Dahlin","year":"2016","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.antiviral.2022.105474_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1552-6909.2002.tb00026.x","article-title":"Cytomegalovirus infection: perinatal implications","volume":"31","author":"Damato","year":"2002","journal-title":"J. Obstet. Gynecol. Neonatal Nurs."},{"key":"10.1016\/j.antiviral.2022.105474_bib17","series-title":"A Long Shot on Cytomegalovirus, the Scientist","first-page":"40","author":"Dove","year":"2006"},{"key":"10.1016\/j.antiviral.2022.105474_bib18","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1084\/jem.20022059","article-title":"Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity","volume":"197","author":"Dunn","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2022.105474_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113014","article-title":"Dispirotripiperazine-core compounds, their biological activity with a focus on broad antiviral property, and perspectives in drug design (mini-review)","volume":"211","author":"Egorova","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2022.105474_bib20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/CVI.00644-12","article-title":"Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies","volume":"20","author":"Gardner","year":"2013","journal-title":"Clin. Vaccine Immunol. : CVI"},{"key":"10.1016\/j.antiviral.2022.105474_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.antiviral.2014.10.011","article-title":"Development of a high-content screen for the identification of inhibitors directed against the early steps of the cytomegalovirus infectious cycle","volume":"113","author":"Gardner","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105474_bib22","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1542\/peds.2014-1173","article-title":"Hearing loss and congenital CMV infection: a systematic review","volume":"134","author":"Goderis","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.antiviral.2022.105474_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.semperi.2021.151393","article-title":"Economic assessments of the burden of congenital cytomegalovirus infection and the cost-effectiveness of prevention strategies","volume":"45","author":"Grosse","year":"2021","journal-title":"Semin. Perinatol."},{"key":"10.1016\/j.antiviral.2022.105474_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.antiviral.2018.09.015","article-title":"A standardized approach to the evaluation of antivirals against DNA viruses: orthopox-, adeno-, and herpesviruses","volume":"159","author":"Hartline","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105474_bib25","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/514249","article-title":"Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV retinitis and viral resistance study group","volume":"177","author":"Jabs","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105474_bib26","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1007\/s11033-012-1482-6","article-title":"Cytomegalovirus infection and coronary heart disease risk: a meta-analysis","volume":"39","author":"Ji","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.antiviral.2022.105474_bib27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/JVI.78.3.1289-1300.2004","article-title":"Specific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule","volume":"78","author":"Jones","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105474_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-022-01677-4","article-title":"Maribavir: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2022.105474_bib29","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1021\/acs.jmedchem.9b01501","article-title":"Validation and characterization of five distinct novel inhibitors of human cytomegalovirus","volume":"63","author":"Kapoor","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2022.105474_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.antiviral.2005.10.003","article-title":"The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo","volume":"69","author":"Kaptein","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105474_bib31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.antiviral.2018.09.016","article-title":"A standardized approach to the evaluation of antivirals against DNA viruses: polyomaviruses and lymphotropic herpesviruses","volume":"159","author":"Keith","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105474_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2022.105474_bib33","first-page":"1120","article-title":"Predicting the oral bioavailability of 19-nortestosterone progestins in vivo from their metabolic stability in human liver microsomal preparations in vitro","volume":"26","author":"Kuhnz","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.antiviral.2022.105474_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/1354750X.2013.877967","article-title":"Presence of cytomegalovirus DNA in leucocytes is associated with increased oxidative stress and subclinical atherosclerosis in healthy adults","volume":"19","author":"Lee","year":"2014","journal-title":"Biomarkers"},{"key":"10.1016\/j.antiviral.2022.105474_bib35","article-title":"Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion","volume":"7","author":"Liu","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.antiviral.2022.105474_bib36","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/s41598-022-05580-6","article-title":"H84T BanLec has broad spectrum antiviral activity against human herpesviruses in cells, skin, and mice","volume":"12","author":"Lloyd","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2022.105474_bib37","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2022.105474_bib38","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/jvi.71.2.1246-1255.1997","article-title":"Effect of a modulator deletion on transcription of the human cytomegalovirus major immediate-early genes in infected undifferentiated and differentiated cells","volume":"71","author":"Meier","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105474_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.pharmthera.2011.04.007","article-title":"Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives","volume":"131","author":"Mercorelli","year":"2011","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.antiviral.2022.105474_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00288-18","article-title":"The artemisinin derivative artemisone is a potent inhibitor of human cytomegalovirus replication","volume":"62","author":"Oiknine-Djian","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105474_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105124","article-title":"Valspodar limits human cytomegalovirus infection and dissemination","volume":"193","author":"Parsons","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105474_bib42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s42003-022-03294-z","article-title":"Development of broadly neutralizing antibodies targeting the cytomegalovirus subdominant antigen gH","volume":"5","author":"Parsons","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.antiviral.2022.105474_bib43","doi-asserted-by":"crossref","first-page":"II207","DOI":"10.1161\/01.CIR.0000138393.99310.1c","article-title":"Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function","volume":"110","author":"Petrakopoulou","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.antiviral.2022.105474_bib44","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1074\/jbc.RA120.014116","article-title":"Artemisinins target the intermediate filament protein vimentin for human cytomegalovirus inhibition","volume":"295","author":"Roy","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2022.105474_bib45","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1128\/JVI.79.5.2754-2767.2005","article-title":"Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements","volume":"79","author":"Sampaio","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105474_bib46","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1161\/CIRCULATIONAHA.107.718874","article-title":"Endothelial dysfunction and cytomegalovirus replication in pediatric heart transplantation","volume":"117","author":"Simmonds","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.antiviral.2022.105474_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.20736","article-title":"Congenital cytomegalovirus infection burden and epidemiologic risk factors in countries with universal screening: a systematic review and meta-analysis","volume":"4","author":"Ssentongo","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.antiviral.2022.105474_bib48","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1038\/s41467-019-10587-1","article-title":"CD46 facilitates entry and dissemination of human cytomegalovirus","volume":"10","author":"Stein","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2022.105474_bib49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000150505","article-title":"The human cytomegalovirus major immediate-early gene","volume":"39","author":"Stenberg","year":"1996","journal-title":"Intervirology"},{"key":"10.1016\/j.antiviral.2022.105474_bib50","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.cell.2012.11.051","article-title":"An endogenous accelerator for viral gene expression confers a fitness advantage","volume":"151","author":"Teng","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2022.105474_bib51","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1073\/pnas.0509201102","article-title":"Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism","volume":"102","author":"Wang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.antiviral.2022.105474_bib52","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1086\/368385","article-title":"Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis","volume":"187","author":"Weinberg","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105474_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105077","article-title":"Antiviral activities of four marine sulfated glycans against adenovirus and human cytomegalovirus","volume":"190","author":"Zoepfl","year":"2021","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222002431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222002431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:36:55Z","timestamp":1759063015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354222002431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":53,"alternative-id":["S0166354222002431"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105474","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating N-arylpyrimidinamine (NAPA) compounds as early-stage inhibitors against human cytomegalovirus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105474"}}